ClinicalTrials.gg
Active, not recruitingNCT04445363AAUpdated Mar 6, 2024

A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata

A Phase 1/2 interventional study of Jaktinib hydrochloride cream and Placebo in Alopecia Areata(AA), sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Alopecia Areata with a site in China — 9 open to participants now, 13 under way, 6 of them phase 3. Alopecia Areata · China.

Enrollment
12th of 22
160 · median 163
Started
2020
with 1 other
Phase 1/2
2 of 24
none open now
Primary completion
2024-12
later than 1 of 12 live
Registered
7th of 24
by date
Lead sponsor
4 of 24
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Among the 24 studies in Alopecia Areata with a site in China, this one is the 12th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2020, is one of 2 in phase 1/2, reaches primary completion later than 1 of the 12 other live ones, and was the 7th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

9 of the 24 studies in Alopecia Areata with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Alopecia Areata with a site in China, or all of them as a file.
02

Study summary

This study includes a dose escalation part(phase I) and a dose extension part(phase II).

Read the detailed description

In phase I of this study, a multi-center, randomized, placebo parallel control design was adopted. Enrolled subjects were randomly assigned to the experimental group or the placebo group.A total of 40 subjects are expected to be enrolled in about 4 centers.

In phase II of this study, a multi-center, randomized, double-blind parallel, placebo-controlled design was adopted. Enrolled subjects were randomly assigned to the experimental group or the placebo group.About 120 subjects are expected to be enrolled in about 10 centers.

03

Conditions studied

  • Alopecia Areata(AA)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 \~ 65 years old (including boundary value), regardless of gender;
  • Diagnosis of Alopecia Areata;
  • Hair loss accounts for 5% \~ 49% of the total scalp area;
  • The duration of hair loss is at least 6 months, the longest is not more than 5 years;
  • Patients can complete treatment for at least 6 months;
  • About Fertility needs meet the following criteria: The results of serum pregnancy tests performed by fertile women during screening visits must be negative, and the results of human chorionic gonadotropin tests performed before the initiation of the study drug must be negative;Women who were fertile and men who had not received vasectomies were required to use effective throughout the study period beginning with the and up to six months after the last administration;
  • Subjects will voluntarily participate in the study after learning about the content and potential adverse drug reactions and must sign an IRC-approved informed consent prior to beginning any examination required by the study;
  • Subject is willing and able to comply with scheduled visits, treatment plan, study drug administration, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • The following causes of hair loss should be excluded: hair loss caused by androgenic alopecia,syphilis, thyroid diseases, etc.
  • Acute Diffuse and Total Alopecia of the Female Scalp;
  • Prior history of serious chronic diseases, such as thyroid disease, liver disease, malnutrition, heart disease, nervous system disease, gastrointestinal dysfunction, tumor and mental illness, etc;
  • infection, virus infection, virus infection;
  • Participated in a trial for a topical or oral JAK inhibitor;
  • Allergic reactions to active ingredients or are known or determined by the investigator;
  • Receipt of treatment known to potentially affect the course of AA within last 3 month;
  • In the opinion of the investigator , the subject is inappropriate for entry into this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Cohort 1,0.5% Bid

    Jaktinib hydrochloride cream 0.5% concentration, twice daily

    Drug: Jaktinib hydrochloride cream

  • Experimental
    Cohort 1,1.5% Bid

    Jaktinib hydrochloride cream 1.5% concentration, twice daily

    Drug: Jaktinib hydrochloride cream

  • Experimental
    Cohort 1,2.5% Qd

    Jaktinib hydrochloride cream 2.5% concentration, once daily

    Drug: Jaktinib hydrochloride cream

  • Experimental
    Cohort 1,2.5% Bid

    Jaktinib hydrochloride cream 2.5% concentration, twice daily

    Drug: Jaktinib hydrochloride cream

  • Placebo comparator
    Dose extension: Placebo

    Placebo, twice daily

    Drug: Placebo

  • Experimental
    Dose extension: 1.5% Bid

    Jaktinib hydrochloride cream 1.5% concentration, twice daily

    Drug: Jaktinib hydrochloride cream

  • Experimental
    Dose extension: 2.5% Bid

    Jaktinib hydrochloride cream 2.5% concentration, twice daily

    Drug: Jaktinib hydrochloride cream

Interventions

  • Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks

    Also known as: Jaktinib

  • DrugPlacebo

    Dose extension: Placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving 90% Improvement of Severity of Alopecia Tool (SALT90)

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease.

    Time frame: at week 24

Secondary outcomes

  1. Change in Severity of Alopecia Tool (SALT) Score

    Severity of Alopecia Tool Score (SALT) calculation is based on a scoring system. The scalp is divided into the following 4 areas: 1) Vertex: 40% (0.4) of scalp surface area, 2) Right profile of scalp: 18% (0.18) of scalp surface area, 3) Left profile of scalp: 18% (0.18) of scalp surface area, and 4) Posterior aspect of scalp: 24% (0.24) of scalp surface area. The percentage of hair loss in any of these areas is the percentage hair loss multiplied by percent surface area of the scalp in that area. The SALT score is the sum of percentage of hair loss in all the above-mentioned areas, so a lower number indicates a better outcome. The reported SALT score range is from a minimum of 0 (no hair loss) to a maximum of 100 (100% hair loss).

    Time frame: at baseline, at week 12 and at week 24

07

Study locations

1 site
  • The Second Xaingya Hospital,central south university
    Changsha, Hunan 410011, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2020 (actual). Primary completion is estimated for Dec 2024, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2020
First posted
Jun 24, 2020
StartActual
Aug 12, 2020
Primary completionEst.
Dec 1, 2024
CompletionEst.
Dec 1, 2024
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04445363
Responsible party
Sponsor
First posted
Jun 24, 2020
Start date
Aug 12, 2020
Primary completion
Dec 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Mar 6, 2024

Study contacts

qianjin lu, M.D.
study chair · the Second Xiangya Hospital, Central South University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion